Our first Stocks and Sips in Perth featured a live panel with Dr Mike Jones (Impact Minerals, ASX:IPT), Brendan Tritton (Valiant Gold, ASX:VAL) and Dr Charmaine Gittleson (Percheron Therapeutics, ASX:PER), hosted by Sharewise CEO Alex Perry. The discussion covered high purity alumina and critical minerals, Western Australian gold and clinical-stage biotech, followed by a live audience Q&A and networking over canapés and drinks at Pan Pacific Perth.


For our first Stocks and Sips in Perth, we welcomed Dr Mike Jones, Managing Director of Impact Minerals (ASX:IPT), Brendan Tritton, Managing Director and CEO of Valiant Gold (ASX:VAL), and Dr Charmaine Gittleson, Chair of Percheron Therapeutics (ASX:PER), for a panel discussion hosted by Sharewise CEO Alex Perry at Pan Pacific Perth.
The three companies cover very different corners of the market. Impact Minerals is advancing its Lake Hope High Purity Alumina (HPA) Project in Western Australia, alongside an exploration portfolio spanning more than 5,500km² across Australia. Valiant Gold, which listed on the ASX in March 2026 after its demerger from Westgold Resources, holds the Reedy and Comet gold projects in the Murchison Goldfields, with a combined Mineral Resource of 1.2Moz. Percheron Therapeutics is a clinical-stage biotech developing HMBD-002, a first-in-class antibody targeting the VISTA immune checkpoint in oncology.
Each panellist introduced their company before Alex led a conversation-style Q&A covering:
The panel was followed by a live audience Q&A and two hours of networking over canapés and drinks, where guests could speak directly with each company's representatives. Thank you to our panellists and to everyone who joined us in the room and on the live stream.
Since launching in Sydney in mid 2025, Stocks and Sips has brought executives from ASX-listed companies face-to-face with hundreds of retail investors, sophisticated investors, and high-net-worth individuals. Now, for the first time, we're bringing the series west.
Three companies - spanning gold exploration, battery metals, and clinical-stage biotech - will join Sharewise CEO Alex Perry on the panel for an evening of candid, conversation-style discussion. Each company opens with a brief introduction, followed by a mix of company-specific and open questions from Alex, before the floor opens to a live audience Q&A. After the panel wraps, guests can connect directly with company representatives over two hours of networking, canapés served by wait staff and an open bar.
The panel and audience Q&A will be live streamed, with the full recording uploaded to Sharewise's YouTube channel after the event.
Guests will also receive complimentary merch to take home.
Where each company is today, what they're building toward, and how management is executing on their strategy.
The catalysts and upcoming developments investors should be watching in the next 6 - 12 months.
How each company is thinking about valuation, capital allocation, and creating long-term value for shareholders.
The market dynamics shaping each sector - from gold and critical minerals to clinical-stage biotech - and how each company is positioned within it.
What retail investors often get wrong, how to evaluate small cap opportunities, and what differentiates the companies worth watching.
The floor opens to in-person guests to ask questions directly - your chance to get answers that matter to you.
Guests arrive, check in, and get seated for the panel.
A relaxed, conversation-style Q&A between Sharewise CEO Alex Perry and a representative from each of the three featured companies - approximately 1 hour. Each company opens with a brief introduction, followed by a mix of company-specific and open questions across the panel.
The floor opens to questions from the audience - approximately 30 minutes. The panel and Q&A are live streamed via Zoom, with the full recording uploaded to Sharewise's YouTube channel after the event.
Two hours of open networking with investors, advisors, and company representatives. Canapés are served by wait staff, with an open bar throughout. Company representatives will be at their tables to connect directly with guests.

An ASX-listed exploration company since 2006, with an extensive tenement portfolio spanning over 5,500km² across Australia. Its centrepiece is the Lake Hope High Purity Alumina (HPA) Project in Western Australia, set to revolutionise HPA production with cost-efficient mining and meet surging global demand. Impact also holds diverse resources across gold, silver, lead, zinc, copper, nickel and PGMs, along with tenements prospective for battery and strategic metals. Backed by an experienced board with a strong track record in exploration and corporate management, Impact is focused on disciplined project selection and delivering lasting shareholder value.

Valiant Gold (ASX: VAL) is an emerging Western Australian gold company, listed on the ASX in March 2026, focused on advancing two proven brownfields assets in the Murchison Goldfields.
Created through the demerger of Westgold Resources' Reedy and Comet projects, Valiant was established to unlock value through dedicated focus and accelerated development.
Valiant holds 100% of the Reedy and Comet gold projects, which have collectively produced over 1Moz of gold and host a combined Mineral Resource of 15.6Mt @ 2.4g/t Au for 1.2Moz.
With existing Mining Leases and proximity to established processing infrastructure, the Company has a clear pathway toward near-term production.
Backed by a highly experienced board and management team, and with Westgold as a cornerstone shareholder, Valiant is well positioned to advance its next phase of growth.

Percheron Therapeutics is a clinical-stage biotechnology company developing breakthrough therapies in oncology and rare diseases. Our lead program, HMBD-002, is a first-in-class monoclonal antibody targeting VISTA, an immune checkpoint regulator that plays a critical role in helping tumours evade the immune system. By blocking VISTA, HMBD-002 has the potential to reactivate the body's natural defences against cancer.

Dr Jones completed undergraduate and post-graduate studies in Mining and Exploration Geology at Imperial College, London. His Ph.D work on gold mineralisation saw him move to Western Australia in 1988 to work for Western Mining Corporation exploring for gold and nickel deposits in the Yilgarn. From 1994 he consulted to the exploration and mining industry specialising in the integration of geological field mapping and the interpretation of geochemical, geophysical and remotely sensed data for target generation.
Dr Jones has worked on over 80 projects both in greenfields and near mine exploration in a wide variety of mineralised terrains and was the founding director of Lithofire Consulting Geologists in Perth, Australia. He was also the team leader during the discovery of a significant gold deposit at the Higginsville Mining Centre, near Kalgoorlie and an iron ore deposit near Newman, both in Western Australia.
.jpeg)
Brendan is a mining executive and WASM graduate with extensive experience across Western Australia's resources sector, spanning technical operations and corporate strategy. He has held senior leadership roles across multiple projects, including at Mincor Resources, and now leads Valiant Gold as it progresses toward production as a newly listed ASX company.

Dr Gittleson has extensive international experience as a pharmaceutical physician and enterprise leader in pharmaceutical drug development, governance and risk management gained during her 15-year tenure (2005-2020) with global specialty biotechnology company CSL Limited (ASX: CSL).
During her time at CSL, Dr Gittleson had at various times accountability for clinical research, medical safety, medical and patient related ethics for development and on market programs, providing leadership in strategic product development, planning and implementation across multiple therapeutic and rare disease areas.
Dr Gittleson held the key leadership roles of: Senior Director, Head Safety and Clinical Development (2006-2010) in Melbourne Australia; Vice President Clinical Strategy (2010-2013) and Senior Vice President Clinical Development (2013-2017) in Pennsylvania United States; and Chief Medical Officer in Melbourne from 2017 until her recent retirement from corporate roles in 2020.
Dr Gittleson commenced her role as Chair on 28 July, 2021.
Attendance is free and spots are limited. Register to receive your QR code for check-in on the night.
Yes - attendance is completely free. You just need to register in advance to secure your spot and receive your QR code for check-in.
Yes - guests are welcome. Please ask them to register separately as spots are limited and every attendee needs their own QR code to enter.
Yes - the panel discussion and audience Q&A are live streamed via Zoom and the full recording is uploaded to Sharewise's YouTube channel after the event. The networking session is not recorded.
No - Stocks and Sips is open to anyone. Whether you're an existing Sharewise client, a shareholder in one of the featured companies, or simply interested in the ASX, you're welcome to register.
The team behind Stocks and Sips works with clients every day on research, advisory and execution across ASX, US and global markets.